{"id":647092,"date":"2023-04-13T20:04:01","date_gmt":"2023-04-13T20:04:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=647092"},"modified":"2023-04-13T20:04:01","modified_gmt":"2023-04-13T20:04:01","slug":"persistent-corneal-epithelial-defects-pceds-pipeline-assessment-2023-updates-indepth-insights-into-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-analysis-and-key-companies","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/persistent-corneal-epithelial-defects-pceds-pipeline-assessment-2023-updates-indepth-insights-into-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-analysis-and-key-companies_647092.html","title":{"rendered":"Persistent Corneal Epithelial Defects (PCEDs) Pipeline Assessment (2023 Updates) | In-depth Insights into Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Analysis, and Key Companies"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Persistent Corneal Epithelial Defects (PCEDs) Pipeline Assessment (2023 Updates) | In-depth Insights into Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Analysis, and Key Companies\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585677425.jpeg\" alt=\"Persistent Corneal Epithelial Defects (PCEDs) Pipeline Assessment (2023 Updates) | In-depth Insights into Clinical Trials, Emerging Drugs, Latest FDA Approvals, Competitive Analysis, and Key Companies\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">As per DelveInsight\u2019s assessment, globally, several major pharma and biotech companies are actively working in the Persistent Corneal Epithelial Defects (PCEDs) therapeutics landscape to develop novel therapies based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">&ldquo;<strong>Persistent Corneal Epithelial Defects Pipeline Insight, 2023<\/strong>&rdquo; report by DelveInsight outlines a comprehensive assessment of the present clinical\/non-clinical development activities and growth prospects across the Persistent Corneal Epithelial Defects Market.&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The Persistent Corneal Epithelial Defects Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" title=\"Persistent Corneal Epithelial Defects Pipeline Analysis\" src=\"https:\/\/www.abnewswire.com\/uploads\/005535b6a9fc5ce0a7b51f16b312481c.jpg\" alt=\"Persistent Corneal Epithelial Defects Pipeline Analysis\" \/><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>Persistent Corneal Epithelial Defects Pipeline Analysis<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report provides insights into:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report provides detailed insights into the emerging therapies for the <strong>treatment of Persistent Corneal Epithelial Defects<\/strong> and the aggregate therapies developed by major pharma companies.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the <strong>Persistent Corneal Epithelial Defects market.<\/strong><\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>The report is built using data and information traced from the researcher&#8217;s proprietary databases, company\/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company\/university websites and industry-specific third-party sources, etc.&nbsp;&nbsp;<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Analysis of Emerging Therapies by Phases<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The report covers the emerging products under different phases of clinical development like &#8211;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Late-stage products (Phase III)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Mid-stage products (Phase II)<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Early-stage product (Phase I)&nbsp;<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Pre-clinical and Discovery stage candidates<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Discontinued &amp; Inactive candidates<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>Learn How the Ongoing Clinical &amp; Commercial Activities will Affect the Persistent Corneal Epithelial Defects Therapeutic Segment @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-pceds-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects Therapeutics Landscape<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">The current standard management of Persistent Corneal Epithelial Defects (PCEDs) includes a stepwise strategy, starting with conservative management and progressing to medical or surgical treatments if refractory. This includes lubrication, bandage soft contact lenses, punctal plugs, debridement, and tarsorrhaphy. Initially, aggressive lubrication every 1&ndash;2 hours with preservative-free artificial tears and ocular ointments are applied to the eye.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Surgical interventions, such as debridement and tarsorrhaphy, are effective in most cases of Persistent Corneal Epithelial Defects (PCEDs) refractory to medical management. Tetracyclines, prophylactic topical antibiotics, and steroids are also used as standard therapy for Persistent Corneal Epithelial Defects (PCEDs). Oral tetracyclines exhibit anti collagenolytic activity, inhibiting MMPs produced by inflammation mediators, and have been shown to be effective in healing Persistent Corneal Epithelial Defects (PCEDs) within weeks.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Several major pharma and biotech giants are developing therapies for Persistent Corneal Epithelial Defects (PCEDs). Currently, OcuNexus Therapeutics is leading the therapeutics market with its Persistent Corneal Epithelial Defects (PCEDs) drug candidates in the advanced stage of clinical development.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The Leading Companies in the Persistent Corneal Epithelial Defects Therapeutics Market Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Amber Ophthalmics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">CoDa Therapeutics Inc<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Eyevance Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Kiora Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">Noveome Biotherapeutics<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">OcuNexus Therapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many Others<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Persistent Corneal Epithelial Defects (PCEDs) Emerging and Marketed Drugs Covered in the Report Include:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Nexagon: OcuNexus Therapeutics\/Eyevance Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">KIO-201: Kiora Pharmaceuticals<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">ST266: Noveome Biotherapeutics<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\">And Many More<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-pceds-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Latest Key Update in the Persistent Corneal Epithelial Defects Therapeutics Market<\/strong><\/p>\n<p style=\"text-align: justify;\"><em>On April 12, 2023,&nbsp;<strong>Kala Pharmaceuticals, Inc. (NASDAQ: KALA)<\/strong>&nbsp;announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation for Kala&rsquo;s human mesenchymal stem cell secretome (MSC-S) therapy (KPI-012) for the treatment of&nbsp;<strong>persistent corneal epithelial defect (PCED)<\/strong>, a rare and debilitating ocular condition.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Content (TOC)<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. Persistent Corneal Epithelial Defects Current Treatment Patterns<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Persistent Corneal Epithelial Defects &#8211; DelveInsight&#8217;s Analytical Perspective<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Therapeutic Assessment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Persistent Corneal Epithelial Defects Late Stage Products (Phase-III)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Persistent Corneal Epithelial Defects Mid-Stage Products (Phase-II)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Persistent Corneal Epithelial Defects Early Stage Products (Phase-I)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Pre-clinical Products and Discovery Stage Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Inactive Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Dormant Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Persistent Corneal Epithelial Defects Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Persistent Corneal Epithelial Defects Product Profiles<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Key Companies in the Persistent Corneal Epithelial Defects Market<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Key Products in the Persistent Corneal Epithelial Defects Therapeutics Segment<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Dormant and Discontinued Products<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Persistent Corneal Epithelial Defects Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Persistent Corneal Epithelial Defects Future Perspectives<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. Persistent Corneal Epithelial Defects Analyst Review&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.<\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Download Sample PDF to Explore the Key Offerings of the Report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=rpr\" target=\"_blank\"><strong>https:\/\/www.delveinsight.com\/sample-request\/persistent-corneal-epithelial-defects-pceds-pipeline-insight<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><em>Take control of your pharmaceutical portfolio with DelveInsight&rsquo;s comprehensive consulting services. Get in touch and discover how we can help you manage your pharmaceutical portfolio today @ <strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/consulting\/pharmaceutical-portfolio-management-solutions\">Pharmaceutical Portfolio Management Services&nbsp;<\/a><\/strong><\/em><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56421.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=persistent-corneal-epithelial-defects-pceds-pipeline-assessment-2023-updates-indepth-insights-into-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-analysis-and-key-companies\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 09650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=persistent-corneal-epithelial-defects-pceds-pipeline-assessment-2023-updates-indepth-insights-into-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-analysis-and-key-companies\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Delveinsight Business Research LLP As per DelveInsight\u2019s assessment, globally, several major pharma and biotech companies are actively working in the Persistent Corneal Epithelial Defects (PCEDs) therapeutics landscape to develop novel therapies based on different Routes of Administration (RoA), Mechanism of &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/persistent-corneal-epithelial-defects-pceds-pipeline-assessment-2023-updates-indepth-insights-into-clinical-trials-emerging-drugs-latest-fda-approvals-competitive-analysis-and-key-companies_647092.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,426,417,404],"tags":[],"class_list":["post-647092","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Financial-Market","category-Marketing-Sales","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/647092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=647092"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/647092\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=647092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=647092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=647092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}